Why Provation’s iPro Lite could signal the end of paper-based anesthesia workflows
Provation launches iPro Lite for mobile anesthesia documentation. Find out how it could change billing, compliance, and risk in outpatient surgery centers.
Organon’s NEXPLANON earns five-year approval: How this changes the LARC landscape
FDA approves NEXPLANON for five years of use with REMS program. Find out how this reshapes contraceptive access, safety, and policy impact.
XenoTherapeutics’ takeover of Repare wins near-unanimous vote: What’s at stake for the pipeline
Repare shareholders approve XenoTherapeutics deal. Find out how this nonprofit acquisition could reshape oncology pipeline models.
What AGC Biologics’ role in Waskyra tells us about the future of ethical cell therapy scale-up
Waskyra’s FDA and EMA approvals spotlight AGC Biologics’ rare disease manufacturing model. Find out what this means for future nonprofit-led therapies.
Can epcoritamab reshape salvage DLBCL care? Genmab’s Phase 3 data brings regulatory momentum
Genmab’s epcoritamab improved PFS in a Phase 3 DLBCL trial. Find out how this could reshape bispecific monotherapy in aggressive B-cell lymphoma care.
Elunetirom shows synaptogenic promise as Autobahn eyes pivotal trials in depression
Autobahn’s elunetirom may offer a novel neuroplasticity-driven treatment for depression. Find out what its latest data mean for the future of MDD therapy.
Saudi FDA approves ImmunityBio’s ANKTIVA in NSCLC: What this means for immunotherapy 2.0
Find out how ImmunityBio’s subcutaneous immunotherapy ANKTIVA secured Saudi approval for NSCLC and what it means for global immuno-oncology.
Allergy relief shake-up: Dr. Reddy’s launches generic Pataday 0.7% eye drops
Dr. Reddy’s launches first U.S. generic of Pataday 0.7% eye drops. Find out what this means for the OTC allergy market and Novartis’s branded edge.
Can wearable ultrasound reinvent breast imaging? What the iSono Health ATUSA launch really signals
iSono Health launches ATUSA™, the first wearable breast ultrasound. Find out how it could transform access, accuracy, and economics in breast imaging.
FDA clears BEAR Implant label for lower osteoarthritis risk: What this changes in ACL surgery
FDA clears PTOA risk reduction claim for Miach Orthopaedics’ BEAR Implant. Find out what this means for ACL treatment, patients, and future adoption.